Intradermal delivery of adenoviral type-35 vectors leads to high efficiency transduction of mature, CD8+ T cell-stimulating skin-emigrated dendritic cells

Journal of Immunology

Volumn 177, Issue 4, 2006, Pages 2208-2215

  De Gruijl, Tanja D ^a   Ophorst, Olga J A E ^b   Goudsmit, Jaap ^b   Verhaagh, Sandra ^b   Lougheed, Sinéad M ^a   Radosevic, Katarina ^b   Havenga, Menzo J E ^b   Scheper, Rik J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CRUCELL HOLLAND BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CIRCUMSPOROZOITE PROTEIN; DRUG CARRIER; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GREEN FLUORESCENT PROTEIN; HLA A2 ANTIGEN; INTERLEUKIN 4; MEMBRANE COFACTOR PROTEIN; VIRUS VACCINE;

ARTICLE; CD8+ T LYMPHOCYTE; CELL MIGRATION; CONTROLLED STUDY; DENDRITIC CELL; EFFECTOR CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNITY; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; SKIN; T LYMPHOCYTE ACTIVATION; TRANSGENE; VIRUS RECOMBINANT;

EID: 33746893817     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.4.2208     Document Type: Article

References (28)

1. Steinman, R. M., and K. Inaha. 1999. Myeloid dendritic cells. J. Leukocyte Biol. 66: 205-208.
2. De Gruijl, T. D., H. M. Pinedo, and R. J. Scheper. 2005. Immunotherapy of cancer by dendritic cell-targeted gene transfer. In Cancer Gene Therapy. D. T. Curiel and J. T. Douglas, eds. Humana Press, Totowa, p. 143-172.
3. Rea, D., M. E. Johnson, M. J. Havenga, C. J. Melief, and R. Offringa. 2001. Strategies for improved antigen delivery into dendritic cells. Trends Mol. Med. 7: 91-94.
4. + T cells are proportionally detectable long after multiple DNA vaccinations. Gene Ther. 9: 879-888.
5. Banchereau, J., and A. K. Palucka. 2005. Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 5: 296-306.
6. + T cells after gene gun immunization. J. Exp. Med. 188: 1075-1082.
7. Akbari, O., N. Panjwani, S. Garcia, R. Tascon, D. Lowrie, and B. Stockinger. 1999. DNA vaccination: transfection and activation of dendritic cells as key events for immunity. J. Exp. Med. 189: 169-178.
8. Condon, C., S. C. Watkins, C. M. Celluzzi, K. Thompson, and L. D. Falo, Jr. 1996. DNA-based immunization by in vivo transfection of dendritic cells. Nat. Med. 2: 1122-1128.
9. Vogels, R., D. Zuijdgeest, R. van Rijnsoever, E. Hartkoorn, I. Damen, M. P. de Bethune, S. Kostense, G. Penders, N. Heimus, W. Koudstaal, et al. 2003. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J. Virol. 77: 8263-8271.
10. Rea, D., M. J. Havenga, A. M. van Den, R. P. Sutmuller, A. Lemckert, R. C. Hoeben, A. Bout, C. J. Melief, and R. Offringa. 2001. Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. J. Immunol. 166: 5236-5244.
11. + T cells upon stimulation with dendritic cells infected with a modified Ad5 vector expressing a chimeric Ad5/35 fiber. Cancer Gene Ther. 11: 227-236.
12. Ophorst, O. J., S. Kostense, J. Goudsmit, R. E. De Swart, S. Verhaagh, A. Zakhartchouk, M. Van Meijer, M. Sprangers, G. Van Amerongen, S. Yuksel, et al. 2004. An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity. Vaccine 22: 3035-3044.
13. Lemckert, A. A., S. M. Sumida, L. Holterman, R. Vogels, D. M. Truitt, D. M. Lynch, A. Nanda, B. A. Ewald, D. A. Gorgone, M. A. Litton, et al. 2005. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-Ad5 immunity. J. Virol. 79: 9694-9701.
14. Sumida, S. M., D. M. Truitt, A. A. Lemckert, R. Vogels, J. H. Custers, M. M. Addo, S. Lockman, T. Peter, F. W. Peyerl, M. G. Kishko, et al. 2005. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J. Immunol. 174: 7179-7185.
15. Ni, S., K. Bernt, A. Gaggar, Z. Y. Li, H. P. Kiem, and A. Lieber. 2005. Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons. Hum. Gene Ther. 16: 664-677.
16. Verhaagh, S., E. de Jong, J. Goudsmit, S. Lecollinet, G. Gillisen, M. de Vries, K. van Leuven, I. Que, K. Ouwehand, R. Mintardjo, et al. 2006. Human CD46 transgenic mice in studies involving replication-incompetent adenoviral type 35 vectors. J. Gen. Virol. 87: 255-265.
17. Valladeau, J., and S. Saeland. 2005. Cutaneous dendritic cells. Semin. Immunol. 17: 273-283.
18. De Gruijl, T. D., S. A. Luykx-de Bakker, B. W. Tillman, A. J. van den Eertwegh, J. Buter, S. M. Lougheed, G. J. van der Bij, A. M. Safer, H. J. Haisma, D. T. Curiel, et al. 2002. Prolonged maturation and enhanced transduction of dendritic cells migrated from human skin explants after in situ delivery of CD40-targeted adenoviral vectors. J. Immunol. 169: 5322-5331.
19. Havenga, M. J., A. A. Lemckert, O. J. Ophorst, M. Van Meijer, W. T. Germeraad, J. Grimbergen, M. A. van Den Doel, R. Vogels, J. van Deutekom, A. A. Janson, et al. 2002. Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. J. Virol. 76: 4612-4620.
20. + lymphocyte clones: effect of natural polymorphism on T cell recognition and endogenous cognate antigen presentation by liver cells. Eur. J. Immunol. 30: 3079-3088.
21. Korokhov, N., S. C. Noureddini, D. T. Curiel, S. J. Santegoets, R. J. Scheper, and T. D. de Gruijl. 2005. A single-component CD40-targeted adenovirus vector displays highly efficient transduction and activation of dendritic cells in a human skin substrate system. Mol. Pharmacol. 2: 218-223.
22. Hsu, K. H., K. Lonberg-Holm, B. Alstein, and R. L. Crowell. 1988. A monoclonal antibody specific for the cellular receptor for the group B coxsackieviruses. J. Virol. 62: 1647-1652.
23. Tillman, B. W., T. D. de Gruijl, S. A. Luykx-de Bakker, R. J. Scheper, H. M. Pinedo, T. J. Curiel, W. R. Gerritsen, and D. T. Curiel. 1999. Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. J. Immunol. 162: 6378-6383.
24. Shedlock, D. J., and D. B. Weiner. 2000. DNA vaccination: antigen presentation and the induction of immunity. J. Leukocyte Biol. 68: 793-806.
25. + T cell responses elicited by different subsets of human skin migratory dendritic cells. J. Immunol. 175: 7905-7915.
26. Rozis, G., S. de Silva, A. Benlahrech, T. Papagatsias, J. Harris, F. Gotch, G. Dickson, and S. Patterson. 2005. Langerhans cells are more efficiently transduced than dermal dendritic cells by adenovirus vectors expressing either group C or group B fibre protein: implications for mucosal vaccines. Eur. J. Immunol. 35: 2617-2626.
27. De Gruijl, T. D., C. C. Sombroek, S. M. Lougheed, D. Oosterhoff, J. Buter, A. J. van den Eertwegh, R. J. Scheper, and H. M. Pinedo. 2006. A post-migrational switch among skin-derived dendritic cells to a macrophage-like phenotype is predetermined by the intracutaneous cytokine balance. J. Immunol. 176: 7232-7242.
28. Iacobelli-Martinez, M., R. R. Nepomuceno, J. Connolly, and G. R. Nemerow. 2005. CD46-utilizing adenoviruses inhibit C/EBPβ-dependent expression of proinflammatory cytokines. J. Virol. 79: 11259-11268.